Carisoprodol (carisoprodol)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Carisoprodol is a centrally acting skeletal muscle relaxant.
USES: Carisoprodol is used short-term to treat muscle pain and discomfort. It is usually used along with rest, physical therapy, and other treatments. It works by helping to relax the muscles.
Generic name: carisoprodol
Pronunciation: (kar-iss-oh-PRO-dole)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Carisoprodol
Indications
The following indications are listed for Carisoprodol:
- Muscle Spasm
Also known as: Involuntary Muscle Contraction, Muscle Spasticity, Skeletal Muscle Spasm, Spasticity.
Dosing
No dosing information is available for this tab.
Carisoprodol is administered orally with or without food.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
A drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes has not been identified to date with use of carisoprodol or meprobamate (an active metabolite) in pregnant women. In an animal reproduction study, reduced fetal weights, postnatal weight gain, and postnatal survival were observed when pregnant mice were exposed to carisoprodol from gestation through weaning. Some experts recommend that the drug be avoided, if possible, during the first trimester of pregnancy.
Limited data indicate that carisoprodol is distributed into human milk and may reach concentrations that are 2-4 times maternal plasma concentrations. Other than mild sedation, no adverse effects have been observed in nursing infants exposed to carisoprodol; while the effects of the drug on milk production are not known, insufficient maternal milk production has been described in several case reports. The known benefits of breastfeeding should be considered along with the mother's clinical need for carisoprodol and any potential adverse effects on the breastfed infant from the drug or underlying maternal condition. The nursing infant should be monitored for signs of sedation during breastfeeding.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.